Ultragenyx Pharma

Forecast & Rating20 analysts currently cover Ultragenyx Pharma, with about 55.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $27.16, about 87.3% upside from the current price of $14.50. Price targets range from $16.00 to $40.00 — a wide spread, showing clear disagreement over just how much Ultragenyx Pharma can rise. Historically, about 2.5% of past price targets were eventually met, which adds credibility. For you, this means institutional views on Ultragenyx Pharma are split — bulls and bears coexist, so you'll need to weigh it against your own judgment. Data as of Sep 17, 2026; for reference only and not investment advice.